Compare Novavax Inc (NVAX) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Yum! Brands, Inc. — how do they compare? Novavax Inc trades at $9.86 (market cap $1.62B), while Yum! Brands, Inc. trades at $144.94 (market cap $39.61B). The key difference: Yum! Brands, Inc. is far larger — about 24.5× Novavax Inc's market cap, and Yum! Brands, Inc. pays a 2.07% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | YUM | |
|---|---|---|
Market Cap | $1.62B | $39.61B |
Sector | Health | Consumer Cyclical |
52-Week High | $11.19 | $168.16 |
52-Week Low | $6.22 | $138.21 |
Enterprise Value | $1.20B | $51.22B |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
YUM trades at $149.59, down 0.74% on the day, with a bearish technical signal from moving averages. The company reported revenue of $8.21B in 2025, with net income of $1.56B and a net margin of 25.4%. Recent developments include the sale of Pizza Hut for approximately $1.5B to LongRange Capital, completed on September 1, 2026, and a declared quarterly dividend of $0.75 per share. Analyst consensus is a buy rating with a price target of $173.60, though technical indicators suggest near-term caution.
Outlook remains supported by strong profitability and strategic portfolio optimization, but risks include high debt levels and competitive pressures. The stock offers potential upside to the consensus target, yet investor sentiment is mixed amid broader market volatility and recent insider selling.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
